Talha S, Di Marco P, Doutreleau S, Rouyer O, Piquard F, Geny B
Service de Physiologie et d'Explorations Fonctionnelles and EA 3072, Hôpitaux Universitaires de Strasbourg, Strasbourg cedex, France.
Clin Transplant. 2008 Sep-Oct;22(5):542-8. doi: 10.1111/j.1399-0012.2008.00818.x. Epub 2008 Apr 3.
Increased brain natriuretic peptide (BNP) in cardiovascular disease is thought to be a compensatory protective mechanism allowing to delay the occurrence of terminal heart failure. Heart transplantation should normalize the neuroendocrine balance but BNP remains elevated in stable heart-transplant recipients (Htx). Such increase has been related to persistent endothelial and cardiac dysfunctions. The purpose of this study was to determine whether selected Htx, presenting with normal hemodynamic and cardiac systolic and diastolic functions on both side of the heart, show a normalization of their BNP plasma values.
Of a cohort of well-being 26 Htx, we selected 12 patients with normal hemodynamics and left and right heart systolic and diastolic functions and compared their circulating BNP, cyclic guanosine monophosphate (cGMP) (the BNP second messenger) and endothelin-1 (ET) values with that of 12 age-, body mass index- and mean arterial pressure-matched controls. Cardiac function determination by echodoppler included cardiac filling pressures assessment using tissue Doppler imaging. Blood samples for biological and hormonal determinations were drawn at rest, within 15 min before echocardiography.
As selected, hemodynamic and left and right heart systolic and diastolic functions were located in the normal range in Htx. Plasma ET value was also similar in Htx and controls (20.7 +/- 0.9 vs. 19.6 +/- 0.9 fmol/mL). However, circulating BNP, like cGMP, was still significantly increased after heart transplantation, when compared with controls (33.8 +/- 8.5 vs. 4.0 +/- 0.9 pg/mL, p = 0.002 and 8.2 +/- 1.1 vs. 4.4 +/- 0.3 nmol/L, p = 0.003) for BNP and cGMP, respectively, in Htx and controls. Interestingly, the sole correlation observed was between BNP and cGMP (r = 0.85, p < 0.0001) after heart transplantation.
After heart transplantation, BNP remained increased despite the normalization of hemodynamic and cardiac systolic and diastolic functions. This suggests that such endocrine heart stimulation should not be viewed only as a hemodynamic marker in Htx. Further studies will be useful to investigate the role of pro-inflammatory cytokines and whether elevated BNP still possesses antifibrotic properties, further supporting the interest of enhancing its activity after heart transplantation.
心血管疾病中脑钠肽(BNP)升高被认为是一种代偿性保护机制,可延缓终末期心力衰竭的发生。心脏移植应使神经内分泌平衡正常化,但在稳定的心脏移植受者(Htx)中BNP仍保持升高。这种升高与持续的内皮功能和心脏功能障碍有关。本研究的目的是确定部分心脏两侧血流动力学及心脏收缩和舒张功能均正常的Htx患者,其血浆BNP值是否恢复正常。
在一组健康的26例Htx患者中,我们选择了12例血流动力学正常且左右心收缩和舒张功能正常的患者,并将他们的循环BNP、环磷酸鸟苷(cGMP)(BNP的第二信使)和内皮素-1(ET)值与12例年龄、体重指数和平均动脉压匹配的对照组进行比较。通过超声心动图测定心脏功能,包括使用组织多普勒成像评估心脏充盈压。在静息状态下、超声心动图检查前15分钟内采集血液样本进行生物学和激素测定。
入选的Htx患者血流动力学及左右心收缩和舒张功能均在正常范围内。Htx患者和对照组的血浆ET值也相似(20.7±0.9对19.6±0.9 fmol/mL)。然而,与对照组相比,心脏移植后循环BNP和cGMP仍显著升高(Htx患者和对照组的BNP分别为33.8±8.5对4.0±0.9 pg/mL,p = 0.002;cGMP分别为8.2±1.1对4.4±0.3 nmol/L,p = 0.003)。有趣的是,心脏移植后仅观察到BNP与cGMP之间存在相关性(r = 0.85,p < 0.0001)。
心脏移植后,尽管血流动力学及心脏收缩和舒张功能恢复正常,但BNP仍升高。这表明这种内分泌性心脏刺激在Htx患者中不应仅被视为血流动力学标志物。进一步的研究将有助于探讨促炎细胞因子的作用以及升高的BNP是否仍具有抗纤维化特性,这将进一步支持增强其在心脏移植后活性的研究意义。